Solu, founded in 2022 by Sam Sihvonen, Kerkko Visuri, and Timo Moilanen, builds a bacterial DNA database and accompanying software to analyze, monitor, and control antibiotic-resistant bacteria. The company's software aims to simplify detection and prevention of antibiotic resistance and to enable development of new treatment methods against resistant bacteria. Solu has begun collaborations with international universities, including Stanford University and the University of Hamburg, which are using its product in antibiotic resistance research. The company raised €1M in funding and intends to use the funds to expand operations and its business reach. In the future, Solu aims to build a pathogen DNA library that collects pathogen data in real time, models evolution, and identifies emerging health-threatening pathogens more effectively.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2023